Peak Asset Management Logo

 8 November, 2023

Did you back the winner yesterday?
The favourite flopped for the 10th year straight as Without A Fight storms home. 

Across markets

Australian shares are poised to edge up, as futures reversed. Tech stocks lured investors in New York. Amazon paced the megatechs. US bond yields dropped.

It wasn’t just the megacaps that advanced. Zscaler, Crowdstrike, Block, Palo Alto Networks and Intel each were at least 2 per cent higher.

Bank of America equity strategist Jill Carey Hall said the bank’s clients were net buyers of US stocks last week, $US2.7 billion worth, buying both large and small cap shares. Most of the buying was done by hedge funds and institutions, while retail clients were net sellers, Hall said.

AustralianSuper was the worst retirement fund for complaints last financial year, as grievances more than doubled to 1750, or more than two times the average of other big providers on a per-member basis.

Oil slid 4 per cent with US crude falling back below $US78 a barrel for the first time in more than two months amid weak trade data from China and renewed concerns about the outlook for US interest rates, Bloomberg reported.

Market highlights

ASX futures down 1 point to 6989 near 8am AEDT

  • AUD -0.8% to 64.37 US cents
  • Bitcoin +1.9% to $US35,629 at 8.12am AEDT
  • On Wall St: Dow +0.2% S&P +0.3% Nasdaq +0.9%
  • In New York: BHP -2.5% Rio -3% Atlassian +3.1%
  • Tesla +1.3% Apple +1.5% Amazon +2.1% Block +3.1%
  • VIX -0.5% QQQ +1% TLT +1.5%
  • Stoxx 50 -0.1% FTSE -0.1% DAX +0.1% CAC -0.4%
  • Spot gold -0.5% to $US1968.90/oz at 4.31pm in New York
  • Brent crude -4% to $US81.75 a barrel
  • Iron ore -1.2% to $US122.30 a tonne
  • 10-year yield: US 4.57% Australia 4.69% Germany 2.66%

US prices as of 4.32pm in New York

Source: AFR

Want to join the Peak Community and get access to our “hand-picked” corporate deals?

Closer to Home
  • Dimerix receives the initial upfront payment of €6.5 million ($10.7million) from Advanz Pharma
  • Biotech eligible for development and sales milestones of up to €132 million ($219 million) plus royalties
  • Dimerix retains full rights to DMX-200 in all unlicensed territories and is seeking partnerships beyond those regions


Special Report:  Dimerix is starting to reap the benefits of its licensing deal with Advanz Pharma to commercialise DMX-200 for treatment of rare kidney disease focal segmental glomerulosclerosis (FSGS) with a multi-million dollar upfront payment.

Aussie biotech Dimerix (ASX:DXB) has received the initial upfront payment of €6.5 million ($10.7million) from Advanz Pharma, which it says marks a pivotal milestone in the company’s growth and development.

DXB remains eligible for potential development and sales milestones of up to €132 million ($219 million),  plus tiered,  escalating,  mid-teen to twenty percentage royalties on net sales.

No royalties or similar costs are payable by DXB to third parties, which means that any revenue from Advanz will flow through to pre-tax profit.

DXB announced in October an exclusive license agreement with the multinational pharmaceutical company covering the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand for commercialisation of DMX-200 for the treatment of FSGS following regulatory approval.

The brand name QYTOVRA has been approved for DMX-200 by the United States Food and Drug Administration (FDA), and may be used as the brand name in some regions.


Source: Stockhead

Follow Peak Asset

Recent Peak Deals

Company: Alderan Resources (ASX:AL8)
Sector: Lithium
Deal Type: Placement
Raise Amount: $1.75M
Latest Entry Price: $0.006 with a 1:2 AL8OA
Today’s Price Change: $0.015 +36.36%

Company: Terra Uranium (ASX:T92)
Sector: Uranium
Deal Type: IPO
Raise Amount: $7.5M
Latest Entry Price: $0.20
Today’s Price Change: $0.130 -3.85%

Company: Patagonia Lithium (ASX:PL3)
Sector: Lithium
Deal Type: IPO
Raise Amount: $8.6M
Latest Entry Price: $0.20
Today’s Price Change: $0.13 Unchanged

Company: Gold Mountain Limited (ASX:GMN)
Sector: Lithium
Deal Type: Placement
Raise Amount: $2.25M
Latest Entry Price: $0.0075
Today’s Price Change: $0.005 -Unchanged

Company: Unith Ltd. (ASX:UNT)
Sector: AI/ChatGPT
Deal Type: Placement
Raise Amount: $4.5M
Latest Entry Price: $0.033 with a 1:1 UNTO
Today’s Price Change: $0.02 +5.26%

Company: Volt Resources Ltd. (ASX:VRC)
Sector: Battery Metals
Deal Type: Placement
Raise Amount: $5.75M
Latest Entry Price: $0.011
Today’s Price Change: $0.007 Unchanged

Company: Castle Minerals Ltd. (ASX:CDT)
Sector: Battery Metals/Base Metals
Deal Type: Placement
Raise Amount: $1.52M
Latest Entry Price: $0.02 with a 2:3 CDTOA
Today’s Price Change: $0.011 +4.76%

Company: Avenira Ltd. (ASX:AEV)
Sector: Phosphate
Deal Type: Placement
Raise Amount: $2.1M
Latest Entry Price: $0.01 with a 1:2 AEVO
Today’s Price Change: $0.0135 +3.85%

Company: Latrobe Magnesium Ltd. (ASX:LMG)
Sector: Magnesium
Deal Type: Placement
Raise Amount: $3M & $11.5M
Latest Entry Price: $0.10 with a 1:4 LMGO
Today’s Price Change: $0.047 -2.08%

Company: Askari Metals Ltd (ASX:AS2)
Sector: Mining
Deal Type: IPO
Raise Amount: $5.7M
Latest Entry Price: $0.35 with a 1:3 AS2O
Today’s Price Change: $0.175 Unchanged

Company: iCandy (ASX:ICI)
Sector: Gaming & Digital Advertising
Deal Type: Placement
Raise Amount: $1.25M
Latest Entry Price: $0.02 with a 1:1 ICIOB
Today’s Price Change: $0.029 -3.33%

Company: Fatfish Group (ASX:FFG)
Sector: Fintech
Deal Type: Placement
Raise Amount: $1.5M
Latest Entry Price: $0.015 with a 1:2 FFGOA
Today’s Price Change: $0.011 +10.00%

Company: Paradigm Biopharma (ASX:PAR)
Sector: Biopharma
Deal Type: IPO Cornerstone
Raise Amount: $1M+
Latest Entry Price: $0.35
Today’s Price Change: $0.43 Unchanged

Company: ReNu Energy Limited (ASX:RNE)
Sector: Energy
Deal Type: Placement
Raise Amount: $1.46M
Latest Entry Price: $0.06 with a 1:1 RNEO
Today’s Price Change: $0.0225 +7.14%

Company: Carly Holdings Ltd (ASX:CL8)
Sector: AI and Car subscription
Deal Type: Placement
Raise Amount: $1.25M
Latest Entry Price: $0.025 with a 1:2 CL8O
Today’s Price Change: $0.017 Unchanged

Company: Avecho Biotechnology (ASX:AVE)
Sector: CBD
Deal Type: Placement
Raise Amount: $5M
Latest Entry Price: $0.006 with a 3:2 AVEOA
Today’s Price Change: $0.004 +33.33%

Company: ECS Botanics Holdings Ltd (ASX:ECS)
Sector: Medicinal Cannabis
Deal Type: Placement
Raise Amount: $6.6M
Latest Entry Price: $0.033 with 1:2 ECSO
Today’s Price Change: $0.023 Unchanged

If you would like more information on future Peak deals, please don’t hesitate to get in touch.

The trustee for Peak Asset Management Unit Trust (“Peak”) is a corporate authorised representative (#1295491) of Dayton Way Securities Pty Ltd (AFSL #382585).
Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does take account your objectives, financial situation or needs.  Before acting on any advice in this email, Peak recommends that you consider whether it is appropriate for your circumstances.  If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this information before making any decisions regarding the products. The Financial Services Guide (FSG) can be found at www.peakassetmanagement.com.au  or by telephoning
Peak on 1300 304 460

Categories:

Tags:

No responses yet

Leave a Reply